Organisation paid for research Program year 2023 Source: CMS Open Payments

Advanced Pharma CR

Neither a doctor nor a teaching hospital

Research payments

$1,089,839

171 payments

Through program year 2023, Advanced Pharma CR is reported as receiving $1,089,839 in research payments, across 171 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$84,988	10
2021	Research	$89,422	20
2020	Research	$270,629	66
2019	Research	$644,800	75

Breakdown

Who paid Research payments · program years 2019–2023

AbbVie, Inc. $549,212 39 payments
Incyte Corporation $537,674 131 payments
Amgen Inc. $2,953 1 payment

Studies the money was for Research payments · program years 2019–2023

M16-100 $502,077 28 payments
TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $140,044 32 payments
A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma $131,806 22 payments
A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis $82,035 9 payments
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $72,075 29 payments
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $47,135 11 payments
Topical Ruxolitinib Evaluation in Vitiligo Study 2 TRuE-V2 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo $41,830 1 payment
A Phase 2, Multicenter, International, Open Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B Cell Lymphoma $18,675 5 payments
A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease $15,169 4 payments
A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo $13,338 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.